New-onset diabetes after covid-19: mechanisms, metabolic implications, and clinical insights

Emad Al-Mulla; Baneen Sarhan Al-Bederi; Abtisam Faris  Al-Shukry

doi:10.29303/aca.v9i1.248

Authors

Emad Al-Mulla AL-Furat Al_Awsat Technical
Baneen Sarhan Al-Bederi
Abtisam Faris Al-Shukry

DOI:

https://doi.org/10.29303/aca.v9i1.248

Keywords:

COVID 19 , Diabetes, Metabolic, Mechanisms, Implications, Clinical Insights , Corona Viruse , 2 (ACE2) recepto , COBAS system , SARS-CoV-2

Abstract

COVID-19 primarily affects the lungs, the impact of COVID-19 is not limited to the lungs only, but rather extends to affect other organs and body systems resulting in other complications that continue during the period of infection or beyond that. New onset diabetes and hyperglycemia is one of the complications of this virus. This study aims to investigate some biomarkers (HbA1c, triglycerides and cholesterol) in group of patients with post covid-19 syndrome and patient with post covid-19 hyperglycemia. Blood samples were withdrawn from 100 (50 controls including 25 males and 25 females and 50 patients including 25 males and 25 females) to investigate HbA1c, triglycerides and cholesterol levels. The result of the present study show that HbA1c significantly increased in PCS males (p.value=0.04) and in PCS females (p.value=0.05) in comparison with control males and control females respectively. The results also show that triglycerides have a significant elevation in PCS males (p.value=0.00) and PCS females(p.value=0.04) in comparison with control males and control females respectively. In the other hand cholesterol was non-significant in both groups. Correlation studies also included and show that there is no significant correlation between HbA1c and other measured parameters. Correlation studies also show that Triglycerides had a strong positive correlation with cholesterol in both PCS groups. Post COVID-19 hyperglycemia is a public health problem in concern and affect the body’s biochemical markers such as HbA1c and triglycerides reflecting their importance in monitoring the overall health in this group of patients.

Downloads

Download data is not yet available.

References

[1] Yang, L., et al., COVID-19: immunopathogenesis and Immunotherapeutics. Signal transduction and targeted therapy, 2020. 5(1): p. 128.

[2] Jin, Y., et al., Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 2020. 12(4): p. 372.

[3] Mohamadian, M., et al., COVID‐19: Virology, biology and novel laboratory diagnosis. The journal of gene medicine, 2021. 23(2): p. e3303.

[4] Goyal, R., et al., Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV. EXCLI journal, 2022. 21: p. 1245.

[5] Alshawi, A. and A.F. Al-Shukry, Increases Aspartate Aminotransferase Activity Negatively Correlated with D-Dimer in Early Diagnosed SARS-CoV-2 Patients. Pharmacophore, 2021. 12(5-2021): p. 85-91.

[6] Perrotta, F., et al., Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? Respiratory medicine, 2020. 168: p. 105996.

[7] Metwally, A.A., et al., COVID-19–induced new-onset diabetes: trends and technologies. Diabetes, 2021. 70(12): p. 2733-2744.

[8] Chee, Y.J., S.J.H. Ng, and E. Yeoh, Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes research and clinical practice, 2020. 164: p. 108166.

[9] Fadini, G.P., et al., Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes research and clinical practice, 2020. 168: p. 108374.

[10] Rubino, F., et al., New-onset diabetes in Covid-19. New England Journal of Medicine, 2020. 383(8): p. 789-790.

[11] Ben Nasr, M., et al., Indirect and direct effects of SARS-CoV-2 on human pancreatic islets. Diabetes, 2022. 71(7): p. 1579-1590.

[12] Gandikota, S., K.S. Sudha, and M.L. Naramalli, Study of HbA1c levels in non-diabetic individuals recovered from Covid-19. Journal of Family Medicine and Primary Care, 2023. 12(11): p. 2727-2732.

[13] Al-Jubury, K., et al., D-dimer and HbA1c levels findings in COVID-19 Iraqi patients. Brazilian Journal of Biology, 2023. 84: p. e266823.

[14] Ebrahimi, K.H. and J.S. McCullagh, A lipidomic view of SARS-CoV-2. Bioscience Reports, 2021. 41(8): p. BSR20210953.

[15] Fijen, L.M., et al., Severe acquired hypertriglyceridemia following COVID-19. BMJ Case Reports CP, 2021. 14(11): p. e246698.

[16] Durrington, P., Blood lipids after COVID-19 infection. The Lancet Diabetes & Endocrinology, 2023. 11(2): p. 68-69.

[17] Xu, E., Y. Xie, and Z. Al-Aly, Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. The Lancet Diabetes & Endocrinology, 2023. 11(2): p. 120-128.

[18] Almulla, A.F., et al., Elevated Atherogenicity in Long COVID: A Systematic Review and Meta-Analysis. medRxiv, 2025: p. 2025.01. 06.25320068.

[19] Roccaforte, V., et al., Altered lipid profile in patients with COVID-19 infection. Journal of Laboratory and Precision Medicine, 2021. 6.